{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:10:12Z","timestamp":1756289412562,"version":"3.44.0"},"reference-count":10,"publisher":"BMJ","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:p>Each year in the UK, an estimated 50,000 patients develop major left ventricular systolic dysfunction (LVSD) and heart failure following a myocardial infarct.1 Such patients have a particularly poor prognosis.2 \u25bcEplerenone (Inspra \u2013 Pfizer) is an aldosterone-receptor antagonist for patients who have LVSD and heart failure following a recent myocardial infarct. Here, we discuss whether such patients should receive this drug.<\/jats:p>","DOI":"10.1136\/dtb.2007.12.0006","type":"journal-article","created":{"date-parts":[[2008,1,2]],"date-time":"2008-01-02T11:13:27Z","timestamp":1199272407000},"page":"1-3","source":"Crossref","is-referenced-by-count":0,"title":["\u25bcEplerenone after myocardial infarction?"],"prefix":"10.1136","volume":"46","member":"239","published-online":{"date-parts":[[2008,1,2]]},"reference":[{"key":"2025082702552228000_46.1.1.1","doi-asserted-by":"crossref","first-page":"ii7","DOI":"10.1136\/hrt.2005.062026","article-title":"Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction.","volume":"91","author":"Cleland","year":"2005","journal-title":"Heart"},{"key":"2025082702552228000_46.1.1.2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.062026"},{"key":"2025082702552228000_46.1.1.3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2025082702552228000_46.1.1.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"2025082702552228000_46.1.1.5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists.","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"2025082702552228000_46.1.1.6","unstructured":"Inspra 25mg & 50mg film-coated tablets Summary of product characteristics UK. Pfizer Limited: April 2007."},{"key":"2025082702552228000_46.1.1.7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2025082702552228000_46.1.1.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030207"},{"key":"2025082702552228000_46.1.1.9","unstructured":"National Institute for Health and Clinical Excellence. Post myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction London: National Collaborating Centre for Primary Care and Royal College of General Practitioners [online] Available: http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG48FullGuideline.pdf [Accessed 13 December 2007] 2007."},{"key":"2025082702552228000_46.1.1.10","unstructured":"Scottish Medicines Consortium, . . Resubmission: eplerenone 25mg and 50mg tablets (Inspra\u00ae): No. (136\/04): Pfizer Ltd NHS Scotland: [online] Available: http:\/\/www.scottishmedicines.org.uk\/smc\/files\/eplerenone_Inspra_RESUBMISSION(136-04).pdf [Accessed 13 December 2007] 2005."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2007.12.0006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:55:40Z","timestamp":1756288540000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2007.12.0006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2008,1,2]]},"published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1136\/dtb.2007.12.0006"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2007.12.0006","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}